Abstract
Background
Although the number of patients aged 80 years or older with aggressive B-cell non-Hodgkin lymphoma (B-NHL) has increased in the clinical setting, management has been challenging due to lower tolerability. The aim of the present study was to evaluate the efficacy and safety of reduced-dose chemotherapy for very elderly patients.
Methods
We retrospectively analyzed the clinical outcomes of patients aged ≥80 years old with diffuse large B-cell lymphoma (n = 58) or grade 3 follicular lymphoma (n = 3).
Results
Patient ages ranged from 80 to 93 years old, with a median of 83 years old. Twenty-four patients were treated with CHOP or THP-COP, the dosages of which were variably reduced, in combination with rituximab (R-vCHOP), while another 24 patients were treated with R-miniCHOP. Twelve R-vCHOP and 16 R-miniCHOP patients completed the chemotherapy cycles. The estimated 2-year progression-free and overall survival rates in the R-vCHOP and R-miniCHOP groups were 53 and 39 % (P = 0.92) and 53 and 48 % (P = 0.95), respectively. Performance status ≥2, lactate dehydrogenase level >normal, serum albumin ≤3.5 g/dL, C-reactive protein ≥2.0 mg/dL, age-adjusted International Prognostic Score 2/3, and withdrawal from the chemotherapy cycle were associated with poor survival. The frequency of chemotherapy-related hospitalization during the second or later cycles was significantly less in the R-miniCHOP group.
Conclusions
The efficacies of R-vCHOP and R-miniCHOP were similar in patients aged ≥80 years old with aggressive B-NHL. The reduced frequency of hospitalization observed for R-miniCHOP treatment is beneficial for very elderly patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stein H, Chan JKC, Warnke RA et al (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 233–237
National Cancer Institute (2014) SEER cancer statistics review 1975–2011. http://seer.cancer.gov/csr/1975_2011/browse_csr.php?sectionSEL=19&pageSEL=sect_19_table.27.html
Ministry of Health, Labour and Welfare (2013) Handbook of health and welfare statistics. http://www.mhlw.go.jp/toukei/saikin/hw/life/life13/index.html
Statistics Bureau (2015) Japan statistical yearbook. http://www.stat.go.jp/english/data/nenkan/1431-02.htm
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391
Meguro A, Ozaki K, Sato K et al (2012) Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 53:43–49
Aoki K, Takahashi T, Tabata S et al (2013) Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 54:2441–2447
Bairey O, Benjamini O, Blickstein D et al (2006) Non-Hodgkin’s lymphoma in patients 80 years of age or older. Ann Oncol 17:928–934
Thieblemont C, Grossoeuvre A, Houot R et al (2008) Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19:774–779
Peyrade F, Jardin F, Thieblemont C et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460–468
Shipp MA (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Tsurumi H, Yamada T, Sawada M et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113
Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458
Morrison VA, Hamlin P, Soubeyran P et al (2015) Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. J Geriatr Oncol 6:141–152
Fields PA, Linch DC (2012) Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 157:159–170
Gutierrez A, Mestre F, Perez-Manga G et al (2011) Diffuse large B-cell lymphoma in the older. Crit Rev Oncol Hematol 78:59–72
Mareschal S, Lanic H, Ruminy P et al (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96:1888–1890
Zhou Z, Sehn LH, Rademaker AW et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837–842
Fletcher CD, Kahl BS (2014) Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 55:2228–2240
Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283
Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26:3159–3165
Balducci L, Repetto L (2004) Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100:6–11
Covinsky KE, Palmer RM, Fortinsky RH et al (2003) Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 51:451–458
van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE et al (2005) Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41:1051–1057
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Iioka, F., Izumi, K., Kamoda, Y. et al. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. Int J Clin Oncol 21, 498–505 (2016). https://doi.org/10.1007/s10147-015-0912-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-015-0912-6